Skip to main content
Premium Trial:

Request an Annual Quote

Symbiodx, Cure Forward Collaborate to Improve Patient Access to Data, Clinical Trials

NEW YORK (GenomeWeb) – Symbiodx, a molecular reference laboratory, is partnering with Cure Forward to provide patients with improved access to their genomic data and greater exposure to relevant clinical trials.

Symbiodx performs more than 300,000 biopsies annually using a custom next-generation sequencing assay. Its results help pathologists and oncologists select appropriate treatments and improve outcomes for patients with solid and hematologic cancers.

Cure Forward connects cancer patients with clinical trial administrators, hoping to reduce trial recruitment times and increase participation. Through its website, patients can retrieve molecular diagnostic test results ordered by their physicians, access educational information, connect with other patients, and investigate treatment options.

"Symbiodx pathologists and staff are involved with the diagnosis and care of more than 10,000 cancer patients per year," Anna Berry, the lab's director of molecular pathology, said in a statement. "Partnering with Cure Forward will allow us to provide an additional service to our cancer patients in helping them connect with clinical trials."